Research papers

The Lancet Gastroenterology & Hepatology, online November 18, 2024, https://doi.org/10.1016/S2468-1253(24)00317-0
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_2, October 2024, Pages ii55–ii66
Framework of IBD Care Delivery Across Ages

Gastroenterology. 2024 Jun;166(6):949-956. doi: 10.1053/j.gastro.2024.02.016. Epub 2024 Feb 18. PMID: 38378092.
Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare Delivery

N Engl J Med . 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease